Shadan Martha’s SEC Form 4 filings reveal a pattern of non-monetary transactions—primarily awards and option exercises—focused almost exclusively on LeMaitre Vascular (LMAT), with a single filing tied to CVRx (CVRX) in mid-2024. Between March 2024 and March 2026, Martha reported 24 transactions, all involving LMAT except for one CVRX award on June 4, 2024. The activity is heavily weighted toward awards (transaction code "A"), with occasional option exercises (code "M"), though none of the filings disclose monetary values. The most recent cluster of transactions occurred on March 26, 2026, with seven LMAT awards reported on the same day, following earlier awards and exercises in February and December 2025.
Martha’s filings show no outright purchases or sales of shares, suggesting the activity is likely tied to equity compensation rather than discretionary trading. The absence of dollar values in the transactions indicates they may involve grants, vesting events, or option conversions without immediate market transactions. While the data does not reflect a clear buy or sell bias, the frequency of awards—particularly the March 2026 filings—points to ongoing equity-based compensation from LMAT. The lone CVRX filing in 2024 stands as an outlier in an otherwise single-company transaction history. Without further context on share dispositions or market activity, the filings primarily document administrative equity events rather than market-driven moves.
AI-assisted summary